Gyre Therapeutics
GYRE
46 hedge funds and large institutions have $20.1M invested in Gyre Therapeutics in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
12% more funds holding
Funds holding: 41 → 46 (+5)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0.96% more ownership
Funds ownership: 2.08% → 3.04% (+0.96%)
7% less capital invested
Capital invested by funds: $21.6M → $20.1M (-$1.48M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.49M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$261K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
+$246K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$186K |
| 5 |
BlackRock
New York
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$359K |
| 2 |
Goldman Sachs
New York
|
-$112K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$34.5K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
-$29.8K |
| 5 |
Barclays
London,
United Kingdom
|
-$22.9K |
GYRE Hedge Fund Activity: Q1 2025 in Review
46 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2025, worth a combined $20.1M — down 6.9% from $21.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GYRE positions and 4 closed out — a net gain of 5 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $8.49M. The largest seller was UBS Group, cutting an estimated $359K.
- 46 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2025, up from 41 in Q4 2024.
- Funds reported $20.1M of Gyre Therapeutics stock for Q1 2025, down 6.9% quarter-over-quarter.
- 9 funds opened new Gyre Therapeutics positions in Q1 2025 and 4 closed out, a net change of +5 holders.
- The largest Gyre Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $8.49M added.
- The largest Gyre Therapeutics seller in Q1 2025 was UBS Group, an estimated $359K sold.
Based on aggregated 13F filings for Q1 2025.